JP2022544031A5 - - Google Patents
Info
- Publication number
- JP2022544031A5 JP2022544031A5 JP2022505359A JP2022505359A JP2022544031A5 JP 2022544031 A5 JP2022544031 A5 JP 2022544031A5 JP 2022505359 A JP2022505359 A JP 2022505359A JP 2022505359 A JP2022505359 A JP 2022505359A JP 2022544031 A5 JP2022544031 A5 JP 2022544031A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- cycloalkyl
- optionally substituted
- ch2cf3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019902641A AU2019902641A0 (en) | 2019-07-25 | Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof | |
| AU2019902641 | 2019-07-25 | ||
| PCT/AU2020/050759 WO2021012014A1 (en) | 2019-07-25 | 2020-07-24 | Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022544031A JP2022544031A (ja) | 2022-10-17 |
| JP2022544031A5 true JP2022544031A5 (enExample) | 2023-07-28 |
Family
ID=74192415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022505359A Pending JP2022544031A (ja) | 2019-07-25 | 2020-07-24 | リシルオキシダーゼのジフルオロハロアリルアミンスルホン誘導体阻害剤、調製方法、及びそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220251036A1 (enExample) |
| EP (1) | EP4003952A4 (enExample) |
| JP (1) | JP2022544031A (enExample) |
| KR (1) | KR20220040480A (enExample) |
| CN (1) | CN114286816B (enExample) |
| AU (1) | AU2020317374A1 (enExample) |
| BR (1) | BR112022000782A2 (enExample) |
| CA (1) | CA3145738A1 (enExample) |
| MX (1) | MX2022001031A (enExample) |
| TW (1) | TW202114991A (enExample) |
| WO (1) | WO2021012014A1 (enExample) |
| ZA (1) | ZA202202376B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021261601A1 (ja) | 2020-06-26 | 2021-12-30 | ラクオリア創薬株式会社 | レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬 |
| CN113440477B (zh) * | 2021-08-12 | 2022-10-11 | 海南海神同洲制药有限公司 | 一种低粘度酮康唑乳膏及其制备方法 |
| US12233056B2 (en) | 2022-04-06 | 2025-02-25 | Syntara Limited | Lysyl oxidase inhibitors for treating myeloid malignancies |
| GB202209624D0 (en) | 2022-06-30 | 2022-08-17 | Institute Of Cancer Res Royal Cancer Hospital | Prodrugs |
| GB202209622D0 (en) | 2022-06-30 | 2022-08-17 | Institute Of Cancer Res Royal Cancer Hospital | Compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101917845A (zh) * | 2007-11-21 | 2010-12-15 | 法马克西斯制药公司 | Ssao/vap-1的卤代烯丙胺抑制剂及其用途 |
| AU2013255103B2 (en) * | 2012-05-02 | 2016-09-29 | Syntara Limited | Substituted 3-haloallylamine inhibitors of SSAO and uses thereof |
| AU2016229268B2 (en) * | 2015-03-06 | 2020-09-10 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
| CA3013917A1 (en) * | 2016-02-09 | 2017-08-17 | Pharmakea, Inc. | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof |
| EA201891674A1 (ru) * | 2016-02-12 | 2019-01-31 | Фармаксис Лтд. | Ингибиторы лизилоксидаз, представляющие собой индольные и азаиндольные производные галогеналлиламина, и их применения |
| EP3589619A4 (en) * | 2017-03-02 | 2020-12-16 | Pharmaxis Ltd. | LYSYL OXIDASE INHIBITORS, HALOGENOALLYLAMINE PYRAZOLE DERIVATIVES AND THEIR USES |
| GB201716871D0 (en) * | 2017-10-13 | 2017-11-29 | Inst Of Cancer Research: Royal Cancer Hospital | Compounds |
| CN112533897B (zh) * | 2018-08-03 | 2023-07-14 | 法玛西斯有限公司 | 赖氨酰氧化酶的卤代烯丙胺砜衍生抑制剂及其用途 |
-
2020
- 2020-07-24 JP JP2022505359A patent/JP2022544031A/ja active Pending
- 2020-07-24 AU AU2020317374A patent/AU2020317374A1/en not_active Abandoned
- 2020-07-24 WO PCT/AU2020/050759 patent/WO2021012014A1/en not_active Ceased
- 2020-07-24 EP EP20844719.3A patent/EP4003952A4/en not_active Withdrawn
- 2020-07-24 CN CN202080060323.3A patent/CN114286816B/zh active Active
- 2020-07-24 TW TW109125162A patent/TW202114991A/zh unknown
- 2020-07-24 CA CA3145738A patent/CA3145738A1/en active Pending
- 2020-07-24 MX MX2022001031A patent/MX2022001031A/es unknown
- 2020-07-24 BR BR112022000782A patent/BR112022000782A2/pt not_active Application Discontinuation
- 2020-07-24 KR KR1020227006461A patent/KR20220040480A/ko not_active Withdrawn
- 2020-07-24 US US17/629,543 patent/US20220251036A1/en not_active Abandoned
-
2022
- 2022-02-24 ZA ZA2022/02376A patent/ZA202202376B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022544031A5 (enExample) | ||
| EP3661560B1 (en) | Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors | |
| US11591311B2 (en) | 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides | |
| WO2018122168A1 (en) | Combinations of bub1 kinase and parp inhibitors | |
| US10370339B2 (en) | N-Methylbenzimidazoles as mIDH1 inhibitors | |
| JP2022537358A5 (enExample) | ||
| WO2017005674A1 (en) | 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors | |
| CN107848985A (zh) | 制备取代的3‑(2‑苯胺基‑1‑环己基‑1h‑苯并咪唑‑5‑基)丙酸衍生物的方法 | |
| EP3411497A1 (en) | Copanlisib biomarkers | |
| US20220251036A1 (en) | Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof | |
| AU2016371762A1 (en) | Use of sGC stimulators for the treatment of gastrointestinal sphincter dysfunction | |
| JP2018522049A5 (enExample) | ||
| WO2024188937A1 (en) | Combinations of atr kinase inhibitors and parp inhibitors to treat hyper-proliferative conditions e.g. cancer | |
| JP7280286B2 (ja) | びまん性大細胞型ｂ細胞リンパ腫を治療するための５－フルオロ－４－（４－フルオロ－２－メトキシフェニル）－ｎ－｛４－［（ｓ－メチルスルホンイミドイル）メチル］ピリジン－２－イル｝ピリジン－２－アミンの使用 | |
| KR20220128622A (ko) | Ahr-억제제 및 pd1-억제제 항체의 조합물 및 암 치료에서의 그의 용도 | |
| WO2018215282A1 (en) | Combination of bub1 and pi3k inhibitors | |
| RU2491934C2 (ru) | Лечение фиброзирующих нарушений | |
| JP2024505252A (ja) | Ｐｔｅｎ不活性化突然変異を有する患者における癌の治療 | |
| EP3585437B1 (en) | Combinations of copanlisib with anti-pd-1 antibody | |
| JP2025528475A (ja) | リシルオキシダーゼの新規選択的阻害剤 | |
| JP2018509439A (ja) | 多発性骨髄腫を治療するための４−（４−フルオロ−２−メトキシフェニル）−ｎ−｛３−［（ｓ−メチルスルホンイミドイル）メチル］フェニル｝−１，３，５−トリアジン−２−アミンの使用 | |
| US11185549B2 (en) | Combination of a PI3K-inhibitor with an androgen receptor antagonist | |
| WO2021260443A1 (en) | Combinations of 2,3-dihydroimidazo[1,2-c]quinazolines |